Business Context and Reporting Period
The provided filing is Aadi Bioscience, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 28, 2023. The request metadata identifies Whitehawk Therapeutics, Inc. and “2022 Q4,” but the filing text does not refer to Whitehawk and provides annual, not standalone fourth-quarter, results.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for cancers involving mTOR-pathway alterations. Its only approved product is FYARRO, approved by the FDA in November 2021 for adult patients with locally advanced unresectable or metastatic malignant PEComa. U.S. commercial launch occurred February 22, 2022.
Financial Performance and Liquidity
| Metric | FY 2022 | FY 2021 | Change |
|---|---|---|---|
| Net product sales | $15.2 million | $0 | New commercial revenue |
| Total revenue | $15.2 million | $1.1 million | Increase driven by FYARRO sales; prior year included license and grant revenue |
| Operating expenses | $77.9 million | $112.3 million | Decrease due primarily to lower impairment charges |
| Loss from operations | $62.7 million | $111.2 million | Improved, but remained substantial |
| Net loss | $60.5 million | $110.1 million | Improved by $49.6 million |
| Net loss per share | $2.69 | $12.41 | Improved; share count increased materially |
| Net cash used in operating activities | $49.6 million | $22.4 million | Cash burn increased |
- Cost of goods sold was $1.3 million, implying a derived product-sales gross margin of approximately 91%, before considering operating expenses. The filing does not present a company-defined gross-margin measure.
- Derived operating and net margins were approximately negative 412% and negative 398%, respectively, based on total revenue; these percentages are distorted by the early commercial launch and substantial development and commercialization spending.
- Cash, cash equivalents and short-term investments totaled $172.6 million at December 31, 2022, comprising $39.0 million of cash and cash equivalents and $133.5 million of short-term investments.
- Management stated that existing liquidity was expected to fund planned operations into 2025, but acknowledged that additional capital will be required to complete all planned development and commercialization activities.
- Net cash used in investing activities was $132.9 million, primarily reflecting $145.2 million of short-term investment purchases, partly offset by $12.8 million of maturities.
- Net cash provided by financing activities was $72.6 million, principally from the September 2022 PIPE financing.
- Liabilities totaled $25.9 million, including $5.8 million due to the BMS licensor, $1.7 million of operating lease liabilities, and $18.8 million of current liabilities. The filing does not identify material conventional bank debt.
- Accumulated deficit was $203.2 million at December 31, 2022. Share-based compensation expense was $9.6 million, with $28.8 million of unamortized expense remaining.
Material Changes Versus the Prior Comparable Period
- FYARRO generated $15.2 million of net product sales in its first year of U.S. commercialization; 2021 had no product sales.
- Selling, general and administrative expense increased to $40.2 million from $18.5 million, driven by higher headcount, commercial launch costs, marketing, insurance, legal expenses and public-company costs.
- Research and development expense increased to $32.7 million from $19.7 million, primarily due to increased personnel, consultants and clinical development spending, including the PRECISION 1 trial.
- Cost of goods sold increased to $1.3 million, including $1.1 million of royalties accrued to BMS.
- The company recorded a $3.7 million impairment of the Gossamer License Agreement intangible asset in 2022, compared with a $74.2 million impairment in 2021. The Gossamer agreement terminated in July 2022 after the related clinical trial failed to meet its endpoints.
- In September 2022, Aadi raised approximately $72.2 million of net proceeds through the sale of common stock and pre-funded warrants. The financing increased common shares outstanding from 20.9 million at year-end 2021 to 24.4 million at year-end 2022, before considering potential warrant dilution.
- PRECISION 1, a registration-directed Phase 2 tumor-agnostic study in patients with TSC1 or TSC2 alterations, began enrollment in the first quarter of 2022, with the first patient dosed in March 2022. Preliminary data were anticipated in the second quarter of 2023.
Guidance, Outlook, Risks and Unusual Items
- No formal revenue, earnings or product-sales guidance is provided. Management expects operating expenses and losses to continue, with 2023 spending expected to rise because of commercialization and clinical-development activities.
- In October 2022, Aadi entered a collaboration with Mirati Therapeutics to evaluate FYARRO with adagrasib in KRAS G12C-mutated NSCLC and other solid tumors. Mirati is responsible for sponsoring and operating the Phase 1/2 study; Aadi will supply study drug and share study costs.
- EOC terminated its FYARRO license for China, Hong Kong, Macau and Taiwan in June 2022 and initiated ICC arbitration alleging contractual breaches. Aadi disputes the allegations, and the filing states that the potential loss cannot be estimated; no liability was accrued.
- Aadi relies on Fresenius Kabi as its single-source manufacturer for FYARRO. The supply agreement includes minimum purchase commitments, including $1.9 million of non-cancellable inventory commitments payable in 2023, and no redundant supply arrangements were in place for key raw materials at year-end.
- Leadership changed materially after year-end: Brendan Delaney became CEO effective January 1, 2023, resigned effective March 14, 2023, and CFO Scott Giacobello became interim CEO and president effective March 15, 2023. The board began a search for a permanent CEO.
- Customer concentration is significant: two customers represented approximately 58% and 41% of 2022 revenue, and one customer represented 100% of accounts receivable at year-end.
- The company disclosed exposure to reimbursement, pricing, regulatory, clinical-trial enrollment, manufacturing, intellectual-property, product-liability, healthcare-reform, cybersecurity, macroeconomic and geopolitical risks.
- The company reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2022. BDO USA LLP issued an unqualified audit opinion and noted that the company was not required to receive an audit of internal control effectiveness.
Most Important Facts for an Investor to Verify
- Confirm that the intended issuer is Aadi Bioscience, Inc., not Whitehawk Therapeutics, Inc., and that the intended reporting period is the fiscal year rather than fourth-quarter-only results.
- Validate FYARRO prescription demand, net pricing, gross-to-net deductions and customer concentration as commercial sales mature.
- Assess whether $172.6 million of liquidity remains sufficient relative to the company’s stated operating plan, clinical-trial costs and expected cash burn.
- Review PRECISION 1 enrollment, efficacy, safety and regulatory feedback, including whether preliminary data supported a registration strategy.
- Monitor the EOC arbitration, potential damages and the prospects for restoring or replacing commercial rights in the licensed Asian territories.
- Evaluate the single-source Fresenius Kabi relationship, minimum purchase obligations and the availability of backup manufacturing and raw-material supply.
- Track CEO succession, commercialization execution and the dilution potential from 2.4 million pre-funded warrants, stock options and future capital raises.
- Review the BMS license obligations, including the $5.8 million balloon payment due August 26, 2024 plus accrued interest, and ongoing royalties.